NCT01876745View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

CompletedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

October 7, 2014

Primary Completion Date

June 1, 2017

Study Completion Date

June 1, 2017

Conditions
Congenital Bleeding DisorderGlanzmann's Disease
Interventions
DRUG

eptacog alfa (activated)

Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY